SCHEMBL30765667

SCHEMBL30765667

CCCCOC(=O)Cn1c(-c2ccccc2)ncc(NCCCCOc2ccccc2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
APAF1 O14727 2/20 0.43
USP2 O75604 2/20 0.43
RAD52 P43351 2/20 0.43
ELANE P08246 3/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CASP1 P29466 1/20 0.41
HSP90AA1 P07900 1/20 0.41
IDE P14735 1/20 0.41
BACE1 P56817 1/20 0.41
FAAH O00519 6/20 0.41
LTA4H P09960 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766150 0.88 GAA (0.52) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765807 0.87 CASP1 (0.47) GAAL3MBTL1ELANECASP1
SCHEMBL30765554 0.87 KDM4E (0.44) GAAL3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL30766080 0.86 MEN1 (0.45) GAAL3MBTL1MEN1KMT2AAPAF1
SCHEMBL30765613 0.85 GAA (0.50) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765668 0.83 GAA (0.50) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765630 0.82 GAA (0.47) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765790 0.82 L3MBTL1 (0.53) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765532 0.82 GAA (0.53) GAAL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL30765447 0.80 L3MBTL1 (0.65) GAAL3MBTL1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed